Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

Analyses of Roxadustat Showed No Increased CV Risk in CKD-Associated Anaemia

astrazeneca
AstraZeneca and partner FibroGen presented a cardiovascular (CV) safety readout at the American Society of Nephrology (ASN) conference from pooled analyses of the HIF-PH inhibitor roxadustat, also kno...

AstraZeneca Presented Detailed Results from Phase III Trials of Roxadustat

astrazeneca
AstraZeneca presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin (Hb) levels in non-dialysis-dependent (NDD) and dialysi...

Sun Pharmaceutical Announced Licensing Agreement with AstraZeneca

sun pharma
Sun Pharmaceutical Industries Ltd. announced that it has entered into a licensing agreement with AstraZeneca UK Ltd. (AstraZeneca) to introduce certain novel ready to-use (RTU) infusion oncology produ...

AstraZeneca Launches Large-Scale Initiatives in China for Global Medicine R&D Advancement

astrazeneca
AstraZeneca announced three large-scale initiatives to build on the Company’s long-standing commitment to China and advance global research and development (R&D) for innovative new medicines. T...

AstraZeneca to Sell Rights to Seroquel and Seroquel XR in Europe and Russia

astrazeneca
AstraZeneca has agreed on the sale and license of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia ...

R-Pharm and AstraZeneca Signed Memorandum of Intentions

r-pharm
During the Open Innovations Forum of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, the R-Pharm group (official representative of the world lead...

FDA Approved Farxiga to Reduce Risk of Heart Failure in Adults with Type-2 Diabetes

astrazeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (...

FDA Granted Priority Review for Trastuzumab Deruxtecan

astrazeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for trastuzum...

FDA Approved Self-Administration of AstraZeneca Fasenra

astrazeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen). The ...

AstraZeneca Agreed to Sell Global Commercial Rights for Losec to Cheplapharm Arzneimittel

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). ...

AstraZeneca and Merck’s LYNPARZA® Phase 3 PAOLA-1 Trial Presented

astrazeneca
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced detailed positive results from the Phase 3 PAOLA-1 trial showing LYNPARZA added to bevacizumab demonstrated a statis...

AstraZeneca Amended Collaboration Agreement with Ironwood Pharma in China Mainland

astrazeneca
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new tr...

FDA Granted Fast Track Designation for Development of Farxiga

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, ...

Imfinzi Showed Improved OS in SCLC Treating

AstraZeneca’s Imfinzi (durvalumab) has become the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer (SCLC), after ...

Schrödinger Announced Collaboration with AZ to Deploy Advanced Computing Platform

astrazeneca
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts. Schrödinger’s computational platform combines p...

AZ Received Approval for Tagrisso in China

AstraZeneca has scored another approval for one of its new drugs in China, this time getting a green light for Tagrisso as a first-line treatment for adults with EGFR-positive non-small cell lung canc...